FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2294742271> ?p ?o ?g. }

• W2294742271 abstract "Persecutory delusions (strong unfounded fears that others intend harm to the person) occur in more than 70 % of the patients diagnosed with schizophrenia. This major psychotic experience is a key clinical target, for which substantial improvement in treatment is needed. Our aim is to use advances in theoretical understanding to develop a much more efficacious treatment that leads to recovery in at least 50 % of people with persistent persecutory delusions. Our cognitive conceptualisation is that persecutory delusions are threat beliefs, developed in the context of genetic and environmental risk, maintained by a number of psychological processes including excessive worry, low self-confidence, intolerance of anxious affect and other internal anomalous experiences, reasoning biases, and safety-seeking strategies. The clinical implication is that safety has to be relearned, by entering the feared situations after reduction of the influence of the maintenance factors. We have been individually evaluating modules targeting causal factors. These will now be tested together as a full treatment, called The Feeling Safe Programme. The treatment is modular, personalised, and includes patient preference. We will test whether the new treatment leads to greater recovery in persistent persecutory delusions, psychological well-being, and activity levels compared to befriending (that is, controlling for therapist attention). The Feeling Safe Study is a parallel group randomised controlled trial for 150 patients who have persecutory delusions despite previous treatment in mental health services. Patients will be randomised (1:1 ratio) to The Feeling Safe Programme or befriending (both provided in 20 sessions over 6 months). Standard care will continue as usual. Online randomisation will use a permuted blocks algorithm, with randomly varying block size, stratified by therapist. Assessments, by a rater blind to allocation, will be conducted at 0, 6 (post treatment), and 12 months. The primary outcome is the level of delusional conviction at 6 months. Secondary outcomes include levels of psychological well-being, suicidal ideation, and activity. All main analyses will be intention-to-treat. The trial is funded by the NHS National Institute for Health Research. The Feeling Safe study will provide a Phase II evaluation of a new targeted translational psychological treatment for persecutory delusions. Current Controlled Trials ISRCTN18705064 (registered 11 November 2015)." @default.
• W2294742271 created "2016-06-24" @default.
• W2294742271 creator A5002936880 @default.
• W2294742271 creator A5021613632 @default.
• W2294742271 creator A5024552084 @default.
• W2294742271 creator A5029652042 @default.
• W2294742271 creator A5053708270 @default.
• W2294742271 creator A5074731029 @default.
• W2294742271 creator A5086206029 @default.
• W2294742271 date "2016-03-11" @default.
• W2294742271 modified "2023-09-26" @default.
• W2294742271 title "The efficacy of a new translational treatment for persecutory delusions: study protocol for a randomised controlled trial (The Feeling Safe Study)" @default.
• W2294742271 cites W1899223624 @default.
• W2294742271 cites W1980623059 @default.
• W2294742271 cites W1986753969 @default.
• W2294742271 cites W2001157702 @default.
• W2294742271 cites W2001328248 @default.
• W2294742271 cites W2001847678 @default.
• W2294742271 cites W2001866454 @default.
• W2294742271 cites W2009832071 @default.
• W2294742271 cites W2013939918 @default.
• W2294742271 cites W2017152382 @default.
• W2294742271 cites W2020616753 @default.
• W2294742271 cites W2020900304 @default.
• W2294742271 cites W2022646248 @default.
• W2294742271 cites W2036480935 @default.
• W2294742271 cites W2055381672 @default.
• W2294742271 cites W2061930158 @default.
• W2294742271 cites W2066357241 @default.
• W2294742271 cites W2075412689 @default.
• W2294742271 cites W2076192638 @default.
• W2294742271 cites W2082235434 @default.
• W2294742271 cites W2082850379 @default.
• W2294742271 cites W2085488608 @default.
• W2294742271 cites W2091606641 @default.
• W2294742271 cites W2092884989 @default.
• W2294742271 cites W2095300556 @default.
• W2294742271 cites W2096304110 @default.
• W2294742271 cites W2096987981 @default.
• W2294742271 cites W2097718574 @default.
• W2294742271 cites W2100376975 @default.
• W2294742271 cites W2104339272 @default.
• W2294742271 cites W2108313446 @default.
• W2294742271 cites W2108385147 @default.
• W2294742271 cites W2117009208 @default.
• W2294742271 cites W2120028475 @default.
• W2294742271 cites W2123552131 @default.
• W2294742271 cites W2135509506 @default.
• W2294742271 cites W2144585543 @default.
• W2294742271 cites W2148083007 @default.
• W2294742271 cites W2148437689 @default.
• W2294742271 cites W2163505421 @default.
• W2294742271 cites W2165478117 @default.
• W2294742271 cites W2166378627 @default.
• W2294742271 cites W2175831798 @default.
• W2294742271 cites W2460693432 @default.
• W2294742271 cites W4251187457 @default.
• W2294742271 doi "https://doi.org/10.1186/s13063-016-1245-0" @default.
• W2294742271 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4788840" @default.
• W2294742271 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26969128" @default.
• W2294742271 hasPublicationYear "2016" @default.
• W2294742271 type Work @default.
• W2294742271 sameAs 2294742271 @default.
• W2294742271 citedByCount "23" @default.
• W2294742271 countsByYear W22947422712016 @default.
• W2294742271 countsByYear W22947422712017 @default.
• W2294742271 countsByYear W22947422712018 @default.
• W2294742271 countsByYear W22947422712019 @default.
• W2294742271 countsByYear W22947422712020 @default.
• W2294742271 countsByYear W22947422712021 @default.
• W2294742271 countsByYear W22947422712022 @default.
• W2294742271 countsByYear W22947422712023 @default.
• W2294742271 crossrefType "journal-article" @default.
• W2294742271 hasAuthorship W2294742271A5002936880 @default.
• W2294742271 hasAuthorship W2294742271A5021613632 @default.
• W2294742271 hasAuthorship W2294742271A5024552084 @default.
• W2294742271 hasAuthorship W2294742271A5029652042 @default.
• W2294742271 hasAuthorship W2294742271A5053708270 @default.
• W2294742271 hasAuthorship W2294742271A5074731029 @default.
• W2294742271 hasAuthorship W2294742271A5086206029 @default.
• W2294742271 hasBestOaLocation W22947422711 @default.
• W2294742271 hasConcept C118552586 @default.
• W2294742271 hasConcept C122980154 @default.
• W2294742271 hasConcept C141071460 @default.
• W2294742271 hasConcept C142724271 @default.
• W2294742271 hasConcept C151730666 @default.
• W2294742271 hasConcept C15744967 @default.
• W2294742271 hasConcept C168563851 @default.
• W2294742271 hasConcept C169900460 @default.
• W2294742271 hasConcept C204787440 @default.
• W2294742271 hasConcept C2777363581 @default.
• W2294742271 hasConcept C2779343474 @default.
• W2294742271 hasConcept C2779978724 @default.
• W2294742271 hasConcept C2780385302 @default.
• W2294742271 hasConcept C2781105514 @default.
• W2294742271 hasConcept C542102704 @default.
• W2294742271 hasConcept C558461103 @default.
• W2294742271 hasConcept C70410870 @default.
• W2294742271 hasConcept C71924100 @default.
• W2294742271 hasConcept C77805123 @default.

• next